Girentuximab Biosimilar – Anti-CA9 mAb – Research Grade from ProteoGenix; catalogue PX-TA1236; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Girentuximab Biosimilar, also known as Anti-CA9 mAb, is a monoclonal antibody that has shown promise as a potential therapeutic agent in the treatment of various cancers. This biosimilar is a highly specific antibody that targets the carbonic anhydrase 9 (CA9) protein, which is overexpressed in many types of tumors. In this article, we will explore the structure, activity, and potential applications of Girentuximab Biosimilar in the field of cancer research.
Girentuximab Biosimilar is a humanized monoclonal antibody, meaning that it is derived from human cells and has been engineered to minimize the risk of immune reactions. It is composed of two identical heavy chains and two identical light chains, connected by disulfide bonds. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) at the end of each arm and a crystallizable fragment (Fc) at the base.
The Fab regions of Girentuximab Biosimilar are responsible for binding to the CA9 protein, while the Fc region is involved in the activation of immune cells and other effector functions. The amino acid sequence of Girentuximab Biosimilar has been carefully selected to ensure high specificity and affinity for CA9, making it an effective therapeutic agent for targeting this protein.
The primary activity of Girentuximab Biosimilar is its ability to bind to the CA9 protein, which is overexpressed in many types of tumors, including renal cell carcinoma, bladder cancer, and head and neck cancer. Once bound to the CA9 protein, Girentuximab Biosimilar can inhibit its activity and disrupt signaling pathways that promote tumor growth and survival.
In addition, Girentuximab Biosimilar can also activate immune cells, such as natural killer cells and macrophages, through its Fc region. This immune activation can lead to the destruction of cancer cells and further enhance the efficacy of Girentuximab Biosimilar as a therapeutic agent.
Girentuximab Biosimilar has shown promising results in preclinical and clinical studies as a potential treatment for various types of cancer. In particular, it has been studied extensively in renal cell carcinoma, where CA9 is highly expressed and is associated with poor prognosis. Girentuximab Biosimilar has shown to be effective in inhibiting tumor growth and prolonging survival in patients with advanced renal cell carcinoma.
Furthermore, Girentuximab Biosimilar is also being investigated as a potential treatment for other types of cancer, such as bladder cancer and head and neck cancer, where CA9 is also overexpressed. It is also being studied in combination with other therapies, such as chemotherapy and immunotherapy, to enhance its effectiveness.
In summary, Girentuximab Biosimilar, also known as Anti-CA9 mAb, is a promising therapeutic agent for the treatment of various types of cancer. Its highly specific and targeted approach, along with its ability to activate the immune system, make it a valuable tool in the fight against cancer. Further research and clinical trials are needed to fully understand the potential of Girentuximab Biosimilar and its role in cancer treatment.
ProteoGenix catalogue number PX-TA1236. For research use only.
Target: Girentuximab Biosimilar – Anti-CA9 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB, Flow Cyt.
Available configurations: 50ug, 100ug, 1mg, 10mg, 25mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Girentuximab Biosimilar – Anti-CA9 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
